Noxafil “Approvable” Response To Be Submitted In 2006, Schering Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough expects to submit a complete response to FDA's "approvable" letter seeking additional data on the oral triazole antifungal Noxafil (posaconazole) next year, Exec VP-Global Development Thomas Koestler said during Schering-Plough's R&D update Nov. 1
You may also be interested in...
Noxafil Is First FDA-Approved Antifungal For Aspergillus Infection Prevention
Schering-Plough plans to launch posaconazole for patients at high risk within two weeks.
Noxafil Is First FDA-Approved Antifungal For Aspergillus Infection Prevention
Schering-Plough plans to launch posaconazole for patients at high risk within two weeks.
Schering Antifungal Noxafil Gets Priority Review For Prophylactic Use
A second NDA for use of posaconzole to treat oropharyngeal candidiasis was granted a standard 10-month review.